Clinical significance of serum IGFBP-3 in colorectal cancer.

IGF-binding protein 3（IGFBP-3）has previously been identified as tumor marker. The present study aimed to investigate the clinical significance of serum IGFBP-3 in colorectal cancer (CRC). Serum was collected from 70 CRC patients and 50 healthy volunteer controls. Serum IGFBP-3 and carcinoembryonic antigen (CEA) levels were measured using electrogenerated chemiluminescence immunoassay and compared between groups. Relationships between serum IGFBP-3 level and the clinical characteristics of CRC were also analyzed. A receiver operator characteristic (ROC) curve was plotted to investigate diagnostic efficacy of serum IGFBP-3 and CEA, respectively, for CRC. Data were analyzed using SPSS 13.0. Serum IGFBP-3 levels in CRC were lower than those of controls (4.68 [3.56, 5.77] vs 5.44 [4.77, 6.10] µg/mL, P < 0.05). Furthermore, serum IGFBP-3 levels were higher in early cancer stages (I and II) than those of advanced stages (III and IV) (4.78 [3.92, 5.49] vs 3.77 [2.65, 4.59] µg/mL, P < 0.05). In addition, patients with lymph node metastasis absent had elevated serum IGFBP-3 levels than those of patients with lymph node metastasis present (4.73 [3.92, 5.72] vs 4.11 [2.45, 4.83] µg/mL, P = 0.02). Finally, ROC curve indicated that serum IGFBP-3 had a better diagnostic power for CRC than CEA. When serum IGFBP-3 and carcinoembryonic antigen were used together to detect CRC, the AUC was 0.949, with a sensitivity of 75% and a specificity of 90%. Serum IGFBP-3 might be a potential biomarker for CRC. © 2019 The Authors. Journal of Clinical Laboratory Analysis Published by Wiley Periodicals, Inc.

Citation

Yu-Lei Hou, Peng Luo, Guang-Yan Ji, Hui Chen. Clinical significance of serum IGFBP-3 in colorectal cancer. Journal of clinical laboratory analysis. 2019 Jul;33(6):e22912

Mesh Tags

Substances

PMID: 31218761

search → result